Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate Immunotherapy with a peptide vaccine and
Programmed Death Ligand 1 (PD-L1) inhibitor as a possible adjuvant treatment for Stage II or
III Triple Negative Breast Cancer. This research study is studying the safety, tolerability,
and immune response of these treatments.
The names of the study interventions involved in this study are:
- PVX-410 Vaccine
- Durvalumab (MEDI4736)